Sutro Biopharma Reports Second Quarter 2019 Financial Results and Recent Business Highlights and Developments
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today reported its financial results for the three and six months ended June 30, 2019.
"During the second quarter of 2019, we presented encouraging interim safety data from our Phase 1 trial for STRO-001 at the EHA Congress and continued to advance our pipeline of product candidates and programs," said Bill Newell, Sutro's Chief Executive Officer. "We believe our proprietary technology allows us to rapidly and precisely create optimally designed, next-generation protein therapeutics candidates for cancer and autoimmune disorders. At Sutro, we hold ourselves to the highest standards and set ambitious goals for ourselves which we have been meeting and exceeding."
Recent Business Highlights and Developments
STRO-001 Clinical Program
-- Potential first-in-class and best-in-class Antibody Drug Conjugate
("ADC") directed against CD74, which is highly expressed in many B cell
malignancies
-- Phase 1 dose-escalation, with dose expansion, clinical trial enrolling
patients with multiple myeloma and non-Hodgkin lymphoma, with initial
safety data presented at the EHA Congress on June 15, 2019 and initial
efficacy data expected by year end 2019
STRO-002 Clinical Program
-- Potential best-in-class ADC directed against folate receptor-alpha,
which is highly expressed in ovarian cancer
-- Phase 1 dose-escalation, with dose expansion, clinical trial enrolling
women with advanced ovarian and endometrial cancers, with initial safety
data expected by year end 2019
BCMA ADC Clinical Program and Celgene Collaboration
-- Celgene received FDA clearance on its IND application for an ADC
targeting B-cell maturation antigen ("BCMA") for the treatment of
multiple myeloma. This is the third product candidate to originate from
Sutro's proprietary discovery and manufacturing platform to enter
clinical development since early 2018, and for which Celgene has
worldwide development and commercialization rights. Sutro is entitled to
development and regulatory milestone payments and tiered royalties
ranging from mid to high single digit percentages from Celgene for this
BCMA ADC.
-- Existing pipeline was bolstered as Sutro gained back rights to three
bispecific assets from the collaboration with Celgene. Sutro holds U.S.
development and commercialization rights targeting BCMA-CD3, PD1-LAG3
and PD1-TIM3. For any products resulting from these three programs,
Celgene will own ex-U.S. development and commercialization rights and
will be obligated to pay Sutro development and regulatory milestone
payments and tiered royalties.
Second Quarter 2019 Financial Highlights
Cash, Cash Equivalents and Marketable Securities
As of June 30, 2019, Sutro had cash, cash equivalents and marketable securities of $168.2 million, as compared to $204.5 million as of December 31, 2018, which represents net cash usage of $36.3 million during the six months ended June 30, 2019.
Revenue
Revenue was $10.5 million and $19.2 million for the three and six months ended June 30, 2019, respectively, compared to $5.7 million and $11.5 million for the same periods in 2018. The 2019 periods included collaboration revenue from Celgene, Merck and EMD Serono. On January 1, 2019, Sutro adopted Accounting Standards Update No. 2014-09 Revenue from Contracts with Customers (Accounting Standards Codification Topic 606). For more information on the impact of the adoption of the new revenue standard, see "Notes to Unaudited Interim Condensed Financial Statements" contained in Part I, Item 1 of Sutro's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 14, 2019. Future collaboration revenue from Celgene, Merck and EMD Serono, and from any future collaboration partners, will fluctuate as a result of the amount and timing of revenue recognition of upfront, milestones and other collaboration agreement payments.
Operating Expenses
Total operating expenses for the three and six months ended June 30, 2019, were $24.2 million and $47.1 million, respectively, compared to $17.8 million and $35.3 million for the same periods in 2018, including non-cash stock-based compensation of $2.5 million and $0.2 million, and depreciation and amortization expense of $1.2 million and $1.1 million, in the 2019 and 2018 second quarters, respectively. Total operating expenses for second quarter 2019 were comprised of research and development expenses of $16.1 million and general and administrative expenses of $8.1 million, with both expense types expected to increase in 2019 as Sutro's internal product candidates advance in clinical development and additional general and administrative expenses are incurred as a public company.
About Sutro Biopharma
Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.
Sutro's proprietary and integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+(TM), led to the discovery of STRO-001 and STRO-002, Sutro's first two internally-developed ADCs. STRO-001 is an CD-74 ADC currently being investigated in a Phase I clinical trial of patients with advanced B-cell malignancies, including multiple myeloma and non-Hodgkin lymphoma. STRO-001 was granted Orphan Drug Designation by the FDA for multiple myeloma in October 2018. STRO-002 is a folate receptor alpha (FoIR ) ADC, currently being investigated in a Phase I clinical trial of patients with ovarian and endometrial cancers. This is the second product candidate to be evaluated in clinical trials resulting from Sutro's XpressCF+(TM) technology platform. A third program, BCMA ADC, which is part of Sutro's collaboration with Celgene, recently received FDA clearance for its IND. Sutro's proprietary technology was responsible for the discovery and manufacturing of the BCMA ADC, for which Celgene has worldwide development and commercialization rights. Sutro is entitled to development and regulatory milestone payments and tiered royalties from Celgene for this BCMA ADC.
Sutro is dedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need.
To date, Sutro has designed cytokine-based immuno-oncology therapies, ADCs, vaccines and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal.
Sutro's platform allows it to accelerate discovery and development of potential first-in-class and best-in-class molecules through rapid and systematic evaluation of protein structure-activity relationships to create optimized homogeneous product candidates.
In addition to developing its own oncology pipeline, Sutro is collaborating with select pharmaceutical and biotech companies to discover and develop novel, next-generation therapeutics. As the pace of clinical development accelerates, Sutro and its partners are developing therapeutics designed to more efficiently kill tumors without harming healthy cells.
Follow Sutro on Twitter, @Sutrobio, and at www.sutrobio.com to learn more about our passion for changing the future of oncology.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated clinical development activities, potential benefits of the company's product candidates and platform and anticipated financial trends. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, the company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the company's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company's ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, the Company's ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, the company's ability to fund development activities and achieve development goals, the company's ability to protect intellectual property, and the Company's commercial collaborations with third parties and other risks and uncertainties described under the heading "Risk Factors" in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Investor Contacts
John Graziano
Solebury Trout
+1 646-378-2942
jgraziano@soleburytrout.com
Xuan Yang
Solebury Trout
+1 646-378-2975
xyang@soleburytrout.com
Media Contacts
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com
Scott Stachowiak
Russo Partners
(646) 942-563
(646) 300-3590 mobile
scott.stachowiak@russopartnersllc.com
Sutro Biopharma, Inc.
Selected Statements of Operations Financial Data
(Unaudited)
(In thousands, except share and per share amounts)
Three Months Ended Six Months Ended
June 30,
June 30,
2019 2018 2019 2018
Revenues $
10,525 $
5,704 $
19,154 $
11,497
Operating expenses
Research and development 16,143 13,751 31,323 26,833
General and administrative 8,067 4,041 15,782 8,455
Total operating expenses 24,210 17,792 47,105 35,288
Loss from operations (13,685) (12,088) (27,951) (23,791)
Interest income 1,124 40 2,300 80
Interest and other expense, net (1,232) 507 (2,392) 124
Net loss $
(13,793) $
(11,541) $
(28,043) $
(23,587)
Net loss per share, attributable to common $
(0.60) $
(24.17) $
(1.22) $
(49.90)
stockholders, basic and diluted
Weighted-average shares used in computing net loss per 22,926,390 477,521 22,895,902 472,647
share attributable to common stockholders
Sutro Biopharma, Inc.
Selected Balance Sheet Financial Data
(Unaudited)
(In thousands)
June 30, December 31,
2019 (1) 2018 (2)
Assets
Cash, cash equivalents and marketable securities $
168,226 $
204,492
Accounts receivable, net 6,500 2,489
Property and equipment, net 9,273 10,934
Other assets 4,813 5,224
Total assets $
188,812 $
223,139
Liabilities and Stockholders' Equity
Accounts payable and other liabilities $
9,494 $
10,703
Deferred revenue 46,957 66,173
Debt 12,806 14,724
Total liabilities 69,257 91,600
Total stockholders' equity 119,555 131,539
Total liabilities and stockholders' equity $
188,812 $
223,139
(1) The condensed balance sheet as
of June 30, 2019 was derived
from the unaudited financial
statements included in the
Company's Quarterly Report on
Form 10-Q for the quarter ended
June 30, 2019, filed with the
Securities and Exchange
Commission on August 14, 2019.
(2) The condensed balance sheet as
of December 31, 2018 was
derived from the audited
financial statements included
in the Company's Annual Report
on Form 10-K for the year ended
December 31, 2018, filed with
the Securities and Exchange
Commission on March 29, 2019.
View original content:http://www.prnewswire.com/news-releases/sutro-biopharma-reports-second-quarter-2019-financial-results-and-recent-business-highlights-and-developments-300901180.html
SOURCE Sutro Biopharma, Inc.
